Clinical Trial

Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

Study acronym: LOGICAN
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Oxaliplatin ± nivolumab in combination with trifluridine/tipiracil or 5-fluorouracile (5-FU) in frail patients with advanced, recurrent or metastatic gastric, oesophageal or gastroesophageal junction cancer.
Protocol Amendment History 3 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-25
notable Primary completion pushed: 2026-01 -> 2026-12 2026-07-25
minor Completion moved earlier: 2027-01 -> 2026-12 2026-07-25
Trial Details
NCT Number NCT05476796
Lead Sponsor UNICANCER
Collaborators: Servier
Conditions Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Enrollment 118 participants
Start Date 2023-06-23
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-24